Docetaxel: a review of its use in metastatic breast cancer.

Docetaxel (Taxotere), a cytotoxic taxane, is an antimicrotubule agent effective in the treatment of patients with breast cancer. The clinical profile of docetaxel as an effective cytotoxic agent in the treatment of metastatic breast cancer is well established. As yet, no single standard regimen has been identified as optimal for the treatment of patients with metastatic breast cancer after failure of prior chemotherapy. However, the efficacy of docetaxel monotherapy administered every 3 weeks as a 1-hour infusion is similar to or better than that of doxorubicin, paclitaxel and fluorouracil plus vinorelbine, and better than that of methotrexate plus fluorouracil or mitomycin plus vinblastine. Although docetaxel is associated with neutropenia and other adverse events, its overall tolerability profile is generally acceptable in the majority of patients. Docetaxel, therefore, is an effective option in the treatment of patients with metastatic breast cancer after failure of prior chemotherapy.

[1]  C. Blomqvist,et al.  Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel , 2004, Acta oncologica.

[2]  J. Klijn,et al.  Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Figgitt,et al.  Docetaxel: an update of its use in advanced breast cancer. , 2000, Drugs.

[4]  G. Martín,et al.  Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer , 2005, Anti-cancer drugs.

[5]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Bachelot,et al.  Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. , 2005, JAMA.

[8]  G. Hortobagyi Recent progress in the clinical development of docetaxel (Taxotere). , 1999, Seminars in oncology.

[9]  E. Alba,et al.  Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Campone,et al.  Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Salgado,et al.  Docetaxel as Single-Agent Treatment in Elderly Patients with Advanced Breast Cancer , 2005, Clinical drug investigation.

[13]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[14]  J. Bergh,et al.  Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. , 2000, European journal of cancer.

[15]  Michael O'Leary,et al.  Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. , 2004, The oncologist.

[16]  J. Eckardt Antitumor activity of docetaxel. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  J. Bergh,et al.  Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  E. Eisenhauer,et al.  The taxoids. Comparative clinical pharmacology and therapeutic potential. , 1998, Drugs.

[19]  J. Verweij,et al.  Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands , 2000, Anti-Cancer Drugs.

[20]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[22]  M. Rocchi,et al.  Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. , 2005, Journal of experimental & clinical cancer research : CR.

[23]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Saijo,et al.  Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Krzakowski,et al.  Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Tres,et al.  Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. , 2004, Clinical breast cancer.

[27]  J. Bergh,et al.  C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. , 2002, European journal of cancer.

[28]  D. Larsimont,et al.  HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel , 2004, Breast Cancer Research and Treatment.

[29]  J. Bonneterre,et al.  Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Jen‐Shi Chen,et al.  Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel , 2000, Anti-cancer drugs.

[31]  D. Larsimont,et al.  Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. , 2002, Clinical breast cancer.

[32]  L. Cals,et al.  Weekly Combination of Docetaxel and Vinorelbine in Metastatic Breast Cancer: A Phase I/II Study , 2004, Oncology.

[33]  E. Mamounas,et al.  Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H Sommer,et al.  Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Sparano Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. , 1999, Seminars in oncology.

[39]  A. Brugarolas,et al.  Docetaxel Plus Vinorelbine as Salvage Chemotherapy in Advanced Breast Cancer: A Phase II Study , 2002, Breast Cancer Research and Treatment.

[40]  C. Spencer,et al.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. , 1996, Drugs.

[41]  M. Stauch,et al.  High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer , 2005, Oncology.

[42]  Miguel Martín Docetaxel in the treatment of operable breast cancer , 2004 .

[43]  M. Venturini,et al.  Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  R. Paridaens,et al.  Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study , 2004, Anti-cancer drugs.

[45]  D. Miles,et al.  Quality of life in women with advanced breast cancer treated with docetaxel. , 2004, Clinical breast cancer.

[46]  E. Kubista,et al.  Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial , 2001, Cancer Chemotherapy and Pharmacology.

[47]  D. Miles,et al.  Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. , 2004, Clinical Breast Cancer.

[48]  J B Vermorken,et al.  A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  M. Namer,et al.  Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure , 2002, British Journal of Cancer.

[50]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[51]  J. Bergh,et al.  Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. , 1999, European journal of cancer.

[52]  N. Caristi,et al.  A Modified Weekly Docetaxel Schedule as First-Line Chemotherapy in Elderly Metastatic Breast Cancer: A Safety Study , 2005, Journal of chemotherapy.

[53]  A. Glasmacher,et al.  Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial , 2003, Anti-cancer drugs.

[54]  P. Barrett-Lee,et al.  Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.